Table 1

Baseline disease and treatment characteristics

TNFi (n=1847)OMA (n=1338)Tofa (n=793)P value
Type or dosage of DMARDAdalimumab (447)Etanercept (515)Golimumab (455)Certolizumab (256)
Infliximab (174)		Abatacept (600)Sarilumab (10)
Tocilizumab (728)		Tofacitinib ≤5 mg bd (761)Tofacitinib >5-10 mg bid (27)
Age (years), mean (SE)54 (14)58 (13)59 (13)<0.001
Female sex, %(n=1376)77 (n=1024)80 (n=636)0.007
BMI (kg/m2), mean (SE)26 (5) (n=1640)27 (5) (n=1197)27 (5) (n=679)0.003
Tobacco smoking current (%)25 (n=1644)22 (n=1227)23 (n=717)0.24
Seropositivity, % (N)69 (n=1243)78 (n=1020)72(n=771)<0.001
Disease duration (years), mean (SE)9 (9) (n=1787)11 (10) (n=1291)12 (10) (n=773)<0.001
DAS28 at baseline, mean (SE)3.6 (1.2) (n=585)3.7 (1.2) (n=828)3.7 (1.2) (n=406)0.057
CDAI at baseline, mean (SE)19 (11) (n=563)21 (12) (n=366)21 (12) (n=246)0.10
Prior bDMARD use*<0.001

  • None (%) (=Bio-naive) [%]

  • 1 prior bDMARDs (%)

  • 2 prior bDMARDs (%)

  • ≥3 prior bDMARDs (%)

56
24
10
10		31
29
22
18		26
22
20
32
Concomitant csDMARDs at baseline*<0.001

  • None (%) (=MONO)

  • COMBO including MTX (%)

  • COMBO with csDMARDs (%)

29
64
6		41
53
6		47
48
20

  • Disease and treatment characteristics at treatment initiation for the different antirheumatic therapy groups. When missing baseline covariates existed, we provide the total number of treatment courses with available data per variable.